1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Blood and immune system conditions
  5. Blood and bone marrow cancers

Acalabrutinib for treating relapsed or refractory mantle cell lymphoma [ID6389]

Awaiting development [GID-TA11470] Expected publication date: TBC

  • Project information
  • Project documents

NIHRIO BN: 10813-Acalabrutinib-for-Mantle-cell-lymphoma-V1.0-OCT2023-NON-CONF.pdf (nihr.ac.uk)